miR-21: a non-specific biomarker of all maladies

Ana E. Jenike and Marc K. Halushka*

Abstract

miRNA-21 is among the most abundant and highly conserved microRNAs (miRNAs) recognized. It is expressed in essentially all cells where it performs vital regulatory roles in health and disease. It is also frequently claimed to be a biomarker of diseases such as cancer and heart disease in bodily-fluid based miRNA studies. Here we dissociate its contributions to cellular physiology and pathology from its potential as a biomarker. We show how it has been claimed as a specific predictive or prognostic biomarker by at least 29 diseases. Thus, it has no specificity to any one disease. As a result, it should not be considered a viable candidate to be a biomarker, despite its continued evaluation as such. This theme of multiple assignments of a miRNA as a biomarker is shared with other common, ubiquitous miRNAs and should be concerning for them as well.

Keywords: microRNA, miR-21-5p, Biomarker, Plasma, Serum, cancer, Heart disease

Introduction

MicroRNAs (miRNAs) are a class of small regulatory RNA. They have important functions in health, disease, and development [1, 2]. miRNAs have a fairly consistent numerical naming convention and hundreds to thousands of highly-conserved miRNAs are known across most species [3, 4]. Because miRNAs are stable in bodily fluids, they have been considered as potential biomarkers of disease [5, 6]. Scores of papers have assigned a litany of miRNA biomarkers to a plethora of different disease states [7–9]. Amongst miRNAs, miR-21-5p (miR-21) is one of the most highly-expressed and highly-studied.

miR-21 was among the first identified microRNAs and is located within the Vacuole Membrane Protein 1 (VMP1) locus on chromosome 17 [10]. It has been implicated in both neoplastic and non-neoplastic pathologies through many of its gene targets. Three of the main targets of miR-21 are Phosphatase and Tensin Homolog (PTEN), Tropomyosin 1 (TPM1), and Programmed Cell Death 4 (PDCD4) [11–14]. The regulation of miR-21 is more complex than most miRNAs. It is transcribed from both a ~3.5 kb and a ~4.3 kb pri-miR-21, from within the VMP1 locus. The transcription of miR-21 is regulated by hypoxia and cytokines, such as interferon [15, 16]. Further post-translational regulation occurs through transforming growth factor beta (TGFβ) mediated events [17].

Functionally, miR-21 has been assigned a variety of activities. In both neoplastic and non-neoplastic disease, the down regulation of miR-21 increased the rate of cell death, the exact target of this is unknown, though possibilities are HIF-1α, PTEN, and PDCD4 [16, 18, 19]. miR-21 increases cell migration through TPM1 and PDCD4 in neoplastic disease. The upregulation by cytokines indicates a role in inflammation. In cardiovascular disease, miR-21 increases fibrosis and cardiac hypertrophy [20, 21]. Due to these important functional activities, miR-21 has been targeted for therapeutic intervention in neoplastic and other diseases [22–24]. Outside of its...
role as a biomarker, we refer the reader to these excellent reviews of miR-21 function [25–27].

**miR-21: a biomarker across a spectrum of diseases**

Not only is miR-21 highly-expressed, it is also ubiquitous across most cell types. However, its common abundant expression is not consistent cell to cell. It has the highest reported levels of expression in macrophages, monocytes and dendritic cells based on cell-specific surveys [28, 29]. From the University of California, Santa Clara (UCSC) Genome Browser Human cellular microRNAome barCharts, the median reads per million (RPM) of miR-21 amongst 75 combined macrophage, monocyte and dendritic cells was 137,021 RPM whereas it was only 38,281 RPM amongst 470 other cells of a combined 75 cell types (Fig. 1). Because of the abundance of miR-21, it is easily measured from bodily fluids such as plasma, serum, urine, peripheral blood mononuclear cells (PBMCs), and other spaces. Across thousands of studies of miRNAs as biomarkers, it frequently appears as having altered expression.

Table 1 lists a subset of studies and diseases in which miR-21 has been implicated as a nonneoplastic biomarker and Table 2 lists cancer biomarker studies. As one can see from the data, miR-21 is implicated as a biomarker in no less than 29 diseases or processes. As far back as 2014, it had already been implicated in 10 nonneoplastic diseases and multiple cancers [30, 31]. Of note, miR-21 is elevated in each of these disease states ranging from cardiovascular disease to cancer. These 45 publications span from 2008 to 2020 and have over 5,000 collective citations (median 68) indicating they are well-known studies and that miR-21 is continued to be pursued as a biomarker.

**Fig. 1** miR-21 expression across 78 cell types. While miR-21 is robustly expressed in most cell types, its highest expression levels appear in macrophages, monocytes, and dendritic cells. Image modified from the UCSC Genome Browser.
What do all of these biomarker studies tell us?

If miR-21 is a marker of at least 29 diseases, then it cannot be a specific biomarker for any disease. Another way to think about this is as follows: If one did a study with 200 subjects and 100 of them had high miR-21 levels and 100 had low miR-21 levels, what disease does the group with the high miR-21 predict? Lung cancer? Myocardial infarction? Lupus? Because that can't be known, how can one believe that miR-21 can be a predictive marker for any disease in a general population [76]? The only way miR-21 can be associated with a disease is if the patient's diagnoses are known a priori, as is the construct of biomarker studies. How about miR-21 serving as a biomarker for a prognostic change between low grade and advancing disease? Based on all of the potential reasons that a miR-21 level can be elevated, how much confidence can an elevated miR-21 level in a patient (and elevated relative to what?) be specific to the disease of inquiry versus any other potential health change? Again, there are too many reasons why miR-21 levels may change to be comfortably assigned to the disease of interest.

Another use of miR-21, as seen from the tables, is as one of multiple miRNAs that collectively serve as a biomarker of disease. These sorts of studies tend to find the optimal area under the curve (AUC) based on 2–6 miRNAs [40, 46, 65]. While this approach likely brings more power to the study than a solitary miR-21 approach, it is still difficult to appreciate that miR-21 adds anything to that collection other than to indicate a cell stressor or perhaps a change in the inflammatory cell milieu. As well, miR-21 levels are frequently used in conjunction

| Disease Group | Disease | Sample Size | Fluid Source | Additional miRNA biomarkers | Predictive or Prognostic | Citation |
|---------------|---------|-------------|--------------|-----------------------------|--------------------------|----------|
| Cardiovascular Diseases | Myocardial infarction | 272 | Plasma | miR-1, miR-499, miR-423, miR-133a | Predictive | [32] |
| | Myocardial infarction | 66 | Plasma | -- | Predictive | [33] |
| | Coronary artery disease | 52 | Plasma | miR-23a, miR-34a | Predictive | [34] |
| | Coronary artery disease | 147 | Plasma | miR-133b | Predictive | [35] |
| | Acute coronary syndrome | 62 | Plasma and PBMC | miR-146, miR-155 | Predictive | [36] |
| | Chronic cardiovascular disease | 60 | Peripheral blood | miR-92a, miR-222, miR-130a | Predictive | [37] |
| | Left ventricular fibrosis in aortic stenosis | 132 | Plasma | -- | Prognostic | [38] |
| | Cardiac arrest | 28 | Plasma | miR-122 | Prognostic | [39] |
| Non-cardiovascular Diseases | Crohn Disease | 78 | Serum | miR-16, miR-484, miR-30e, miR-140, miR-192, miR-93, let-7b, miR-195, miR-106a, miR-20a | Predictive | [40] |
| | Dengue Fever | 6DC / 72VC | Serum | miR-146a | Predictive | [41] |
| | Hepatitis C | 72 | Serum | miR-27a, miR-106, miR-122, miR-93, miR-199, miR-23b | Predictive and prognostic | [42] |
| | Hepatitis C | 110 | Serum | -- | Prognostic | [43] |
| | Multiple sclerosis | 48 | PBMC | miR-146a, miR-146b | Predictive | [44] |
| | Non-alcoholic fatty liver | 403 | Serum | miR-34a, miR-122, miR-145, miR-451 | Predictive | [45] |
| | Pneumonia | 176 | Serum | miR-155, miR-197, miR-182 | Predictive | [46] |
| | Pulmonary fibrosis | 62 | Serum EV | -- | Prognostic | [47] |
| | Pulmonary fibrosis | 130 | Serum | miR-155 | Predictive | [48] |
| | Renal fibrosis | 42 | Serum | -- | Predictive | [49] |
| | Systemic lupus erythematosus | 145 | Plasma | miR-126 | Predictive | [50] |
| | Systemic lupus erythematosus | 85 | PBMC | miR-155 | Predictive | [51] |
| | Type 2 diabetes complications | 300 DC / 40 VC | Plasma / CAC | miR-126 | Prognostic | [52] |

Key: DC Discovery Cohort; VC Validation Cohort; EV Extracellular Vesicles; PBMC Peripheral Blood Mononuclear Cells; CAC Circulating Angiogenic Cells
with other common miRNAs such as miR-155, miR-92a, and miR-122, which also decreases specificity towards a particular disease (Table 1).

One important point about all of these studies is that there is ample evidence that miR-21 expression really is altered in many disease states [11, 20, 77, 78]. That is likely telling us something very fundamental about the expression and function of this highly conserved miRNA. It would seem to suggest that miR-21 is commonly upregulated in a stress environment [1]. Another possibility is macrophages/dendritic cells/circulating monocytes are increased in disease states as part of a global inflammatory response. As the percentage of these cells increase, the levels of miR-21 will increase in tandem in the same bodily fluids. If this is true, then miR-21 may have a very narrow value as a biomarker, where it can be used in conjunction with other cell-specific miRNAs to address the extent of inflammation, if that was a diagnostic factor for a particular disease.

Although we have focused the discussion on miR-21 as a biomarker, all ubiquitous miRNAs should be viewed with caution as potential prognostic biomarkers for any disease [30]. Unfortunately, many miRNAs, such as the let-7 family, miR-10a, miR-22, and others are also both commonly identified as disease biomarkers and common to many different cell types [79]. Each of these three miRNAs are also implicated in a range of neoplastic and non-neoplastic disorders.

**Table 2** Biomarker status of elevated miR-21 across 13 neoplasias

| Disease Group | Disease                          | Sample size | Fluid Source | Additional miRNA biomarkers                  | Predictive or Prognostic | Citation |
|---------------|----------------------------------|-------------|--------------|---------------------------------------------|--------------------------|----------|
| 1             | AIDS-related non-Hodgkin lymphoma| 125         | Serum        | miR-122, miR-223                            | Predictive              | [53]     |
| 2             | B-cell lymphoma                  | 157         | Serum        | --                                          | Prognostic               | [54]     |
| 2             | B-cell lymphoma                  | 103         | Serum        | miR-155, miR-210                            | Predictive              | [55]     |
| 3             | Breast cancer                    | 122         | Serum        | --                                          | Predictive/prognostic   | [56]     |
| 3             | Breast cancer                    | 120         | Serum        | miR-92a                                     | Predictive              | [57]     |
| 4             | Colorectal cancer                | 330         | Serum        | miR-92a                                     | Prognostic               | [58]     |
| 4             | Colorectal cancer                | 60DC / 40VC | Plasma       | miR-1, miR-133a, miR-31, miR-135b           | Predictive              | [59]     |
| 4             | Colorectal cancer                | 24DC / 342VC| Serum        | --                                          | Predictive/prognostic   | [60]     |
| 5             | Esophageal cancer                | 42          | Serum        | --                                          | Predictive              | [61]     |
| 6             | Gastric cancer                   | 42          | Plasma       | --                                          | Prognostic               | [62]     |
| 6             | Gastric cancer                   | 20DC / 120VC| Plasma       | miR-223, miR-218                            | Predictive              | [63]     |
| 7             | Glioma                           | 112         | Plasma       | miR-155b                                    | Predictive              | [64]     |
| 7             | Glioma                           | 60          | Plasma       | miR-128, miR-342                            | Predictive/prognostic   | [65]     |
| 8             | Hepatocellular carcinoma         | 80DC / 453VC| Serum        | --                                          | Predictive/prognostic   | [66]     |
| 8             | Hepatocellular carcinoma         | 57          | Serum EV     | miR-144                                     | Predictive              | [67]     |
| 8             | Hepatitis B/hepatocellular cancer| 137DC / 407DC / 390VC| Plasma | miR-122, miR-192, miR-223, miR-27a, miR-26a, miR-801 | Predictive | [68]     |
| 9             | Hodgkin lymphoma                 | 62          | Plasma       | miR-494, miR-1973                           | Predictive              | [69]     |
| 10            | Lung cancer                      | 176         | Serum        | miR-155, miR-197, miR-182                    | Predictive/prognostic   | [70]     |
| 11            | Osteosarcoma                     | 40DC / 48VC | Plasma       | miR-221, miR-106a                           | Prognostic              | [71]     |
| 11            | Osteosarcoma                     | 95          | Serum        | --                                          | Prognostic              | [72]     |
| 12            | Pancreatic cancer                | 50DC / 176VC / 68DC / 137VC | Serum | miR-20a, miR-24, miR-25, miR-99a, miR-185, miR-191 | Predictive/prognostic   | [73]     |
| 12            | Pancreatic cancer                | 74          | Plasma       | miR-483                                     | Predictive              | [74]     |
| 13            | Prostate cancer                  | 28          | Serum        | miR-106b, miR-144, miR-375                   | Predictive              | [75]     |
| 13            | Prostate cancer                  | 71          | Plasma       | miR-141, miR-221                            | Predictive              |          |

Key: DC Discovery Cohort; VC Validation Cohort; EV Extracellular Vesicles;
Need to separate the functional importance of a miRNA from its value as a biomarker

miR-21 is clearly involved in key regulatory pathways. Modulating its expression in \textit{in vivo} and \textit{in vitro} studies show clear and important phenotype changes. We may ultimately find that a miR-21 pathway can be successfully targeted for therapeutic intervention. In fact, at least two clinical trials, one in Alport Syndrome (NCT033773786), and another in diabetic wound healing (NCT02581098) are attempting exactly that and may indicate the usefulness in modulating miR-21 levels for efficacy. However, this important role in disease does not make it a useful biomarker to predict these diseases.

Conclusions

Sadly, miR-21 cannot be considered a specific biomarker for any disease if it is a biomarker of many diseases. While its levels may genuinely vary across bodily fluids in disease states, these variations have no specificity. The miRNA community should stop trying to develop miRNA biomarker studies around miR-21 or other miRNAs with the same characteristics. Future miRNA biomarker researchers should be cognizant of other claims on their miRNA of interest and move toward miRNAs that are more unique.

The best miRNA biomarkers will be those that indicate injury or perturbation to a specific cell type. Already one such miRNA, miR-371a-3p has shown promise as a biomarker for testicular cancer. Whether it will make it into clinical practice is unknown \cite{80, 81}. Other cell specific miRNAs, such as miR-122, a hepatocyte-specific miRNA, is useful in identifying liver injury, while the myomiRs, miR-133, miR-206, miR-208, miR-499 have shown some promise for their ability to identify cardiac injury \cite{30, 82}.

In conclusion, miR-21 is a critically important miRNA in health, development, and disease, but based on a significant body of work, is not a useful fluid-based biomarker. Research into this role should not be pursued.

References

1. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148(6):1172–87.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
3. Kozomara A, Griffiths-Jones S. miBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014; 42(Database issue):D68–73.
4. Fromm B, Domanska D, Hoyer E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, et al. MiRGenDB 2.0: the metazoan microRNA complement. Nucleic Acids Res. 2020;48(Database issue):D132–41.
5. Mitchell PS, Parkin RK, Krichevsky AM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8.
6. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.
7. Xie QY, Almudever A, Whitney-Miller CL, Barry CT, McCray MN. A microRNA biomarker of hepatozell carcinoma recurrence following liver transplantation accounting for within-patient heterogeneity. BMC Med Genomics. 2016;9:18.
8. Allen-Rhoades W, Kurenbekova L, Sarferedi L, Parkin N, Fuja D, Shuck RL, Rainusso N, Trucco M, Barkauskas DA, Jo E, et al. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer medicine. 2015;4(7):977–88.
9. Zampetaki A, Klech S, Drozdov I, Willett P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107(6):810–7.
10. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294(5543):853–8.
11. Meng F, Heinson R, Wehebe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–58.
12. Zhu Q, Wang Z, Hu Y, Li J, Li X, Zhou L, Huang Y, miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep. 2012;27(5):1660–8.
13. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 2010;411(11–12):946–52.
14. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007;282(19):14328–36.
15. da Costa Martins PA, De Windt LJ. miR-21: a miRaculous Socratic paradox. Cardiovasc Res. 2010;87(3):397–400.
16. Yang CH, Yue J, Fan M, Pfeffer LM. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res. 2010; 70(20):8108–16.
61. Cai EH, Gao YX, Wei ZZ, Chen WW, Yu P, Li K. Serum miR-21 expression in human esophageal squamous cell carcinomas. Asian Pacific journal of cancer prevention: APJCP. 2012;13(4):1563–7.

62. Ma GJ, Gu RM, Zhu M, Wen X, Li JF, Zhang YY, Zhang XM, Chen SQ. Plasma post-operative miR-21 expression in the prognosis of gastric cancers. Asian Pacific journal of cancer prevention: APJCP. 2013;14(12):7551–4.

63. Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo X, Mao XH, Zou QM, Yu PW, Zuo QF, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 2012;7(7): e41629.

64. Ivo DUnso P, Fernando DUnso O, Damiano Gianfreda C, Mezzolla V, Storelli C, Marsigliante S. miR-13b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma. Curr Genomics. 2015;16(3):304–11.

65. Wang Q, Li P, Li A, Jiang W, Wang H, Wang J, Xie K. Plasma specific mRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res. 2012;31:97.

66. Guo X, Lu X, Lv X, Ma Y, Chen L, Chen Y. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis. Oncotarget. 2017;8(27):44050–8.

67. Pu C, Huang H, Wang Z, Zou W, Lv Y, Zhou Z, Zhang Q, Qao L, Wu F, Shao S. Extracellular Vesicle-Associated miR-21 and miR-144 Are Markedly Elevated in Serum of Patients With Hepatocellular Carcinoma. Frontiers in physiology. 2018:9390.

68. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(36):4781–8.

69. Jones K, Nourse JP, Keane C, Bhattacharyya TM, Gandhi MK. Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2014;20(1):253–64.

70. Nakka M, Allen-Rhoades W, Li Y, Kelly AJ, Shen J, Taylor AM, Barkauskas DA, Yustein JT, Andriulis IL, Wunder JS, et al. Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106b in osteosarcoma. Oncotarget. 2017;8(57):96738–52.

71. Yuan J, Chen L, Chen X, Sun W, Zhou X. Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. J Int Med Res. 2012;40(6):2090–7.

72. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clinical chemistry. 2012;58(3):610–8.

73. Alme M, Yokoyama M, Shibuya T, Tann K, Yamaguchi K, Sato I, Tanaka N, Hamada S, Shimosegawa T, Sugamura K, et al. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int J Oncol. 2015;46(2):539–47.

74. Porzycki P, Ciszewicz E, Semik M, Tyryk M. Combination of three microRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition. Int Urol Nephrol. 2018;50(9):1619–26.

75. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, Gezer U. Investigation of miR-21, miR-141, and miR-375 as potential diagnostic tool for prostate cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology Medicine. 2011;32(3):583–8.

76. Aalam AH, Abdahad H, Mesgari M. Circulating miR-21 as a potential biomarker in human digestive system carcinoma: a systematic review and diagnostic meta-analysis. Biomarkers 2021;1–10.

77. Ribas J, Ni X, Haffner M, Wentzel EA, Salmassi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009;69(18):7165–9.

78. Jazbutyte V, Thurm T. MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets. 2010;11(8):926–35.

79. McCall NN, Kim MS, Adil M, Patil AH, Liu Y, Mitchell CI, Leal-Rojas P, Xu J, Kumar M, Dawson VL, et al. Toward the human cellular microRNAome. Genome Res. 2017;27(10):1769–81.

80. Syring L, Bartels J, Holdenrieder S, Kristiansen G, Muller SC, Ellinger J. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer. J Urol. 2015;193(1):317–7.

81. Deckmann KP, Radtké A, Gecei L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenit E, Pichler R, et al. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2019;37(16):1412–23.

82. Halushka PV, Goodwin AJ, Halushka MK. Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers. Annual review of pathology. 2019;14:211–38.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.